US 10,894,822 B2 · Treatment of tauopathies

Abstract

The invention is directed to methods of treatment of Alzheimer's disease and other tauopathies, via the administration of antibodies having specificity to abnormal forms of tau protein, the antibodies showing no binding and/or reactivity to a normal tau protein and being administered under conditions and in amounts effective to prevent or treat Alzheimer's disease or other tauopathies. In certain embodiments, the antibodies are selective for soluble truncated tau protein truncated at (i) its C-terminus after the glutamic acid residue Glu391, or (ii) at the aspartic acid residue Asp421, or (iii) at its N-terminus at the aspartic acid residue Asp13, or (iv) a combination of (i)-(iii). Further aspects of the invention are directed to the administration of an immunogen comprising an abnormal tau, preferably a soluble truncated tau.

Claims8

Dependent claims

A method of slowing the progression or ameliorating a symptom of Alzheimer's disease in a human, comprising administering an antibody to a human in need of therapy for Alzheimer's disease in an amount effective to delay the onset, slow the progression or ameliorate the symptom of Alzheimer's disease, wherein

the antibody binds an artificial peptide consisting of SEQ ID NOs. 78-86 with an equilibrium constant KD from 1×10−9 M to 1×10−11 M, as measured by the surface plasmon resonance assay utilizing peptide captured on streptavidin chip, but does not bind hTau40,
the antibody is TauC3 and is administered in a pharmaceutical formulation comprising (i) TauC3 and (ii) one or more pharmaceutically acceptable excipients.

Dependencies are inferred from the claim text.

Treatment of tauopathies

Life of this patent

Treatment of tauopathies

Life of this patent

Abstract

Claims8